 |
| Product Information |
| Product Name: | tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu |
| Synonyms: | (S)-22-(Tert-butoxycarbonyl)-10,19,24-trioxo-3,6,12,15-tetraoxa-9,18,23-triazahentetracontane-1,41-dioic acid;Octadecane(OtBu)-Glu(ɑ-OtBu)-AEEA-AEEA-OH;Side chain;tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu;Semaglutide side chain;Fmoc-L-Lys[OctotBu)-Glu-(otBu)-AEEA-AEEA]-OHu;(S)-22-(tert-butoxycarbonyl)-43,43-dimethyl-10,19,24,41-tetraoxo-3,6,12,15,42-pentaoxa-9,18,23-triazatetratetracontanoic acid;Egf(a) analogue-13C4 |
| CAS: | 1118767-16-0 |
| MF: | C43H79N3O13 |
| MW: | 846.1 |
| tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu – High-Purity Semaglutide Side Chain Intermediate |
tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu (CAS 1118767-16-0) is a critical Semaglutide side chain intermediate, widely applied in the synthesis of GLP-1 receptor agonist drugs. As a PEG AEEA linker C18 fatty side chain, it improves peptide pharmacokinetics by enhancing albumin binding and prolonging half-life. With deep expertise in peptide CDMO and amino acid derivatives CDMO services, we provide reliable supply for both research and large-scale production.
| Production & Manufacturing Process |
Our manufacturing process ensures high-purity tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu for semaglutide synthesis with consistent reproducibility:
Raw Materials: Pharmaceutical-grade stearic acid, glutamic acid derivatives, and PEG AEEA linkers selected under strict QC.
Chemical Coupling: Stepwise esterification and amidation techniques build the C18 fatty acid PEG-AEEA linker with high efficiency.
Protection Strategy: Use of tBu groups stabilizes reactive sites, ensuring compatibility with SPPS (solid-phase peptide synthesis).
Purification: Advanced HPLC and crystallization yield ≥98% purity, meeting pharmaceutical standards.
Stability & Storage: Product demonstrates excellent stability when stored at −20 °C under dry, inert atmosphere conditions.
Scale-up Capability: From gram-scale to multi-kilogram GMP-ready production with full analytical support.
| Applications & Use Cases |
Semaglutide Synthesis
Functions as a semaglutide side chain intermediate essential for GLP-1 analogs targeting type 2 diabetes and obesity.
Albumin Affinity Enhancement
The semaglutide linker albumin affinity enhancement ensures prolonged circulation time, enabling long-acting peptide therapeutics.
Peptide Drug Development
The C18 fatty acid PEG-AEEA linker for long-acting peptide drugs is widely adopted in next-generation GLP-1 and other peptide-based APIs.
Custom CDMO Solutions
Supported by cdmo contract manufacturing for peptide and cdmo contract manufacturing for amino acid derivatives, including tailored synthesis, analytical method development, and regulatory documentation.
| Why Choose Us? |
High purity: ≥98% with complete COA, HPLC, and NMR reports
Flexible production: From pilot to commercial scale under GMP-like environment
Technical support: Storage, handling, and application guidance for research & manufacturing
Global supply: Trusted pharmaceutical intermediate factory with proven CDMO track record
tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu is indispensable in semaglutide synthesis, serving as a robust and reliable PEG AEEA linker C18 fatty side chain. With our advanced CDMO expertise, we deliver scalable, high-quality solutions to accelerate peptide drug innovation.
| Product Information |
| Product Name: | tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu |
| Synonyms: | (S)-22-(Tert-butoxycarbonyl)-10,19,24-trioxo-3,6,12,15-tetraoxa-9,18,23-triazahentetracontane-1,41-dioic acid;Octadecane(OtBu)-Glu(ɑ-OtBu)-AEEA-AEEA-OH;Side chain;tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu;Semaglutide side chain;Fmoc-L-Lys[OctotBu)-Glu-(otBu)-AEEA-AEEA]-OHu;(S)-22-(tert-butoxycarbonyl)-43,43-dimethyl-10,19,24,41-tetraoxo-3,6,12,15,42-pentaoxa-9,18,23-triazatetratetracontanoic acid;Egf(a) analogue-13C4 |
| CAS: | 1118767-16-0 |
| MF: | C43H79N3O13 |
| MW: | 846.1 |
| tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu – High-Purity Semaglutide Side Chain Intermediate |
tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu (CAS 1118767-16-0) is a critical Semaglutide side chain intermediate, widely applied in the synthesis of GLP-1 receptor agonist drugs. As a PEG AEEA linker C18 fatty side chain, it improves peptide pharmacokinetics by enhancing albumin binding and prolonging half-life. With deep expertise in peptide CDMO and amino acid derivatives CDMO services, we provide reliable supply for both research and large-scale production.
| Production & Manufacturing Process |
Our manufacturing process ensures high-purity tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu for semaglutide synthesis with consistent reproducibility:
Raw Materials: Pharmaceutical-grade stearic acid, glutamic acid derivatives, and PEG AEEA linkers selected under strict QC.
Chemical Coupling: Stepwise esterification and amidation techniques build the C18 fatty acid PEG-AEEA linker with high efficiency.
Protection Strategy: Use of tBu groups stabilizes reactive sites, ensuring compatibility with SPPS (solid-phase peptide synthesis).
Purification: Advanced HPLC and crystallization yield ≥98% purity, meeting pharmaceutical standards.
Stability & Storage: Product demonstrates excellent stability when stored at −20 °C under dry, inert atmosphere conditions.
Scale-up Capability: From gram-scale to multi-kilogram GMP-ready production with full analytical support.
| Applications & Use Cases |
Semaglutide Synthesis
Functions as a semaglutide side chain intermediate essential for GLP-1 analogs targeting type 2 diabetes and obesity.
Albumin Affinity Enhancement
The semaglutide linker albumin affinity enhancement ensures prolonged circulation time, enabling long-acting peptide therapeutics.
Peptide Drug Development
The C18 fatty acid PEG-AEEA linker for long-acting peptide drugs is widely adopted in next-generation GLP-1 and other peptide-based APIs.
Custom CDMO Solutions
Supported by cdmo contract manufacturing for peptide and cdmo contract manufacturing for amino acid derivatives, including tailored synthesis, analytical method development, and regulatory documentation.
| Why Choose Us? |
High purity: ≥98% with complete COA, HPLC, and NMR reports
Flexible production: From pilot to commercial scale under GMP-like environment
Technical support: Storage, handling, and application guidance for research & manufacturing
Global supply: Trusted pharmaceutical intermediate factory with proven CDMO track record
tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu is indispensable in semaglutide synthesis, serving as a robust and reliable PEG AEEA linker C18 fatty side chain. With our advanced CDMO expertise, we deliver scalable, high-quality solutions to accelerate peptide drug innovation.
